2020
DOI: 10.1101/2020.05.13.094177
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection againstNeisseria gonorrhoeae

Abstract: AEJ) 22 23 24 † These authors contributed equally to the work. 25 26 27 2 28 Abstract 29 30There is a pressing need for a gonorrhea vaccine due to the high disease burden 31 associated with gonococcal infections globally and the rapid evolution of antibiotic resistance in 32 Neisseria gonorrhoeae (Ng). Current gonorrhea vaccine research is in the stages of antigen 33 discovery and the identification of protective immune responses, and no vaccine has been tested 34 in clinical trials in over 30 years. Recently,… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 88 publications
(92 reference statements)
0
5
0
Order By: Relevance
“…Moreover, evidence supporting some extent of cross-protection against MenACWY and MenX strains continues to accumulate for 4CMenB [50,[74][75][76]. In addition, 4CMenB may also induce partial crossprotection against N. gonorrhea [77]. Notably, the impact of 4CMenB vaccination in real-world settings has been shown in the UK, with a 69% reduction of MenW-IMD incidence in children fully eligible for vaccination (adjusted incidence rate ratio: 0.31; 95% CI: 0.20-0.67) and 98 MenW cases prevented directly by 4CMenB vaccination in children ≤12 years (eligible for 4CMenB but not MenACWY), during 2011/2012-2018/2019 [78].…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, evidence supporting some extent of cross-protection against MenACWY and MenX strains continues to accumulate for 4CMenB [50,[74][75][76]. In addition, 4CMenB may also induce partial crossprotection against N. gonorrhea [77]. Notably, the impact of 4CMenB vaccination in real-world settings has been shown in the UK, with a 69% reduction of MenW-IMD incidence in children fully eligible for vaccination (adjusted incidence rate ratio: 0.31; 95% CI: 0.20-0.67) and 98 MenW cases prevented directly by 4CMenB vaccination in children ≤12 years (eligible for 4CMenB but not MenACWY), during 2011/2012-2018/2019 [78].…”
Section: Discussionmentioning
confidence: 99%
“…While the mechanism of cross-protection of 4CMenB against gonococcus is not clear, sera from individuals vaccinated with 4CMenB were shown to react with gonococcal proteins in ELISA and Western blots ( 112 ). Immunization with 4CMenB in the female mouse model of gonococcal infection has shown that vaccination significantly accelerated clearance and reduced bacterial burden ( 113 ). Serum IgG and vaginal IgA from the mice cross-reacting with gonococcal OMVs recognized several gonococcal proteins and had serum bactericidal activity against both the challenge strain F62 and strain FA1090.…”
Section: Prospects For a Protective Vaccinementioning
confidence: 99%
“…68 BEVs from pathogenic bacteria have been successfully used in vaccine formulations, and several extracellular vesicles vaccines against Vibrio cholerae and serogroup B Neisseria meningitidis are licensed, with those for serogroup B N meningitidis showing potential cross species protection against Neisseria gonorrhoeae. 69 Other studies have shown that BEVs produced by microbiota Review members, including bioengineered BEVs, have been used to deliver antigens from pathogens. Carvalho and colleagues 70 showed that BEVs deriving from Bacteroides thetaiotaomicron and expressing different Yersinia pestis antigens elicited specific and strong immune responses in vivo, including serum IgG and mucosal IgA, which were able to clear plague infection.…”
Section: Bacterial Extracellular Vesicles (Bevs)mentioning
confidence: 99%
“…Focusing on specific microbial products, such as BEVs, represents a more refined approach. The success of the already established BEV vaccine against cholera and type B meningitis, 69 and the promising results with commensal BEV antigen carriers against plague and influenza, 70 could give rise to a novel vaccine generation based on immunomodulatory BEVs of commensal origin with high efficacy and biosafety standards on a global scale. Nevertheless, further studies will be required to identify which strains produce novel adjuvantlike BEVs from early-life microbiota members such as Bifidobacterium and Bacteroides.…”
Section: Conclusion and Future Perspectivesmentioning
confidence: 99%